Mammotome Enhances Access to Innovative Breast Biopsy Marking Technology across Europe

Mammotome, a member of the Danaher Corporation and a global leader in innovative breast health solutions, has recently announced the CE marking approval for its HydroMARK™ Plus markers. This approval signifies a major advancement in the accessibility of a state-of-the-art marking technology for patients undergoing breast cancer diagnosis and treatment throughout Europe.

What Are HydroMARK™ Plus Markers?

The HydroMARK™ Plus markers are specifically engineered to improve tissue adhesion and minimize marker displacement during surgical excision. Uniquely, they incorporate a proprietary hydrogel technology alongside “Wings that Cling™,” which are exposed wing structures utilized in the designs of the Dragonfly™ and Hummingbird™ marker forms. When implanted, the hydrogel expands within 24 hours, ensuring visibility for up to 12 months in ultrasound imaging, even for patients receiving neoadjuvant chemotherapy. These features collectively support precise localization of lesions, which is crucial for effective treatment.

Designed to be visible through ultrasound, mammography, and MRI, HydroMARK™ Plus markers are indicated for use in breast tissue and lymph nodes, providing multiple imaging modalities to enhance diagnostic accuracy. Olaf Andrich, General Manager of EMEA at Mammotome, stated, "Minimizing the risk of surgical displacement is of utmost priority for breast health teams when supporting patients throughout their treatment. The HydroMARK™ Plus markers were specifically developed with an emphasis on marker stability and visibility, allowing physicians to rely on the marker remaining on target during surgery. The acquisition of CE marking is a significant step towards broadening access to this technology across Europe."

Commitment to Innovation and Patient Care

Mammotome offers a comprehensive range of biopsy site markers, catering to various clinical situations. The HydroMARK™ Plus markers, which have been approved by both the FDA and Health Canada, reflect the company's dedication to enhancing access to advanced technologies in breast care worldwide. These markers are expected to be available in Europe soon, with a gradual rollout planned across selected markets.

Mammotome's product offerings aim to deliver better outcomes in breast health and are accompanied by informative materials designed to assist both clinicians and patients throughout their journeys. Headquartered in Cincinnati, Ohio, Mammotome has been part of the Danaher Corporation since 2014, ensuring that their innovations are supported by extensive resources and technological prowess.

Danaher Corporation’s Role

Danaher Corporation is a leading global innovator in the life sciences and diagnostics sectors, committed to advancing the possibilities of science and technology to improve human health. Through its interconnected ecosystem of leading companies, Danaher collaborates closely with clients to resolve their most complex scientific and clinical challenges, facilitating more efficient pathways from discovery to market for innovations. Supporting these efforts are around 60,000 employees worldwide who focus on sustainable improvements and enhancing the quality of life across the globe, all while moving towards a healthier and more sustainable future.

For more details on this innovative technology, clicks are encouraged on the provided resources and links related to HydroMARK™ Plus.